Last update 16 May 2025

TRK-950

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
TRK 950
Target
Action
blockers
Mechanism
CAPRIN1 blockers(cell cycle associated protein 1 blockers)
Inactive Indication
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastroesophageal junction adenocarcinomaPhase 2
United States
04 Oct 2023
Gastroesophageal junction adenocarcinomaPhase 2
Japan
04 Oct 2023
Locally Advanced Unresectable Gastric AdenocarcinomaPhase 2
United States
04 Oct 2023
Locally Advanced Unresectable Gastric AdenocarcinomaPhase 2
Japan
04 Oct 2023
Locally Advanced Malignant Solid NeoplasmPhase 1
Japan
06 Jul 2022
Bladder CancerPhase 1
United States
26 Apr 2019
Bladder CancerPhase 1
France
26 Apr 2019
Colorectal CancerPhase 1
United States
26 Apr 2019
Colorectal CancerPhase 1
France
26 Apr 2019
Gastrooesophageal junction cancerPhase 1
United States
26 Apr 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
9
TRK-950+paclitaxel+amucirumab
mjwprwybeu(xbqgtbeqnm) = kgelxieprw ywbgnwpjjk (muufeypkiu )
Positive
24 Jan 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free